Canada Drug Agency Recommends Public Reimbursement for Alzheimer's Drug Leqembi

Key Facts

1Canada's Drug Agency (CDA-AMC) issued a final positive recommendation supporting public reimbursement for the Alzheimer's drug Leqembi.

2The drug was developed by Eisai in partnership with BioArctic AB.

In a move reflecting ongoing regulatory momentum within the global healthcare sector, the Alzheimer's treatment Leqembi has secured vital support for its Canadian market expansion. Canada's Drug Agency (CDA-AMC) issued a final positive recommendation supporting public reimbursement for the drug. According to reports, this decision facilitates broader access to the therapy, which was developed through a partnership between Japan's Eisai and Sweden's BioArctic AB.

This recommendation arrives amid increasing clinical focus on dementia innovations, targeting patients with mild cognitive impairment or mild dementia. Per market data and analyst facts, the drug's efficacy in slowing cognitive decline has cleared the path for this public funding support. This development follows the drug's previous integration into healthcare systems in major economies including the United States, Japan, and China.

Regarding market performance, Eisai Co., Ltd. (4523.T) stood at 4740 JPY at the close of August 31, 2026. During that session, the stock reached a high of 4795 JPY and a low of 4721 JPY. As there are no immediate sector-specific catalysts in the upcoming economic calendar, investors will likely focus on how this Canadian regulatory milestone impacts the long-term commercial trajectory of the Eisai-BioArctic alliance.